Kyverna Therapeutics, Inc. (KYTX)
Automate Your Wheel Strategy on KYTX
With Tiblio's Option Bot, you can configure your own wheel strategy including KYTX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol KYTX
- Rev/Share 0.0468
- Book/Share 4.2655
- PB 1.6856
- Debt/Equity 0.0321
- CurrentRatio 5.3866
- ROIC -0.9019
- MktCap 314862388.0
- FreeCF/Share -3.2909
- PFCF -2.2134
- PE -1.9584
- Debt/Assets 0.0261
- DivYield 0
- ROE -0.6493
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 4
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | KYTX | William Blair | -- | Outperform | -- | -- | Aug. 20, 2025 |
| Upgrade | KYTX | H.C. Wainwright | Neutral | Buy | -- | $5 | May 27, 2025 |
| Initiation | KYTX | UBS | -- | Buy | -- | $13 | Oct. 10, 2024 |
| Initiation | KYTX | Rodman & Renshaw | -- | Buy | -- | $16 | Oct. 9, 2024 |
News
Kyverna Therapeutics: Taking The Next Step In Autoimmune Cell Therapies
Published: December 18, 2025 by: Seeking Alpha
Sentiment: Positive
Kyverna Therapeutics is upgraded to 'Buy' based on strengthened financials and the potential for commercial launch by the end of 2026. Phase 2 data for mivocabtagene autoleucel shows strong efficacy and favorable safety in autoimmune indications, supporting late-stage advancement. A recent $100 million public offering and an untapped $125 million loan facility extend KYTX's cash runway into 2027, enabling continued pipeline progress.
Read More
Kyverna Therapeutics, Inc. (KYTX) Discusses Positive Topline Data From KYSA-8 Trial of Miv-cel in Stiff Person Syndrome Transcript
Published: December 17, 2025 by: Seeking Alpha
Sentiment: Neutral
Kyverna Therapeutics, Inc. (KYTX) Discusses Positive Topline Data From KYSA-8 Trial of Miv-cel in Stiff Person Syndrome Transcript
Read More
Kyverna Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock
Published: December 17, 2025 by: GlobeNewsWire
Sentiment: Neutral
EMERYVILLE, Calif., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX) (“Kyverna”), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today announced the pricing of an underwritten public offering of 13,333,333 shares of its common stock at a public offering price of $7.50 per share.
Read More
Kyverna Therapeutics: "Strong Buy" Rating As Positive SPS Data Leads To 1st Half 2026 BLA Filing
Published: December 16, 2025 by: Seeking Alpha
Sentiment: Positive
Kyverna Therapeutics (KYTX) is upgraded to "Strong Buy" following positive phase 2 data for miv-cel in SPS and MG indications. Company achieved a 46% average improvement in SPS patients in phase 2 KYSA-8 study, surpassing clinical benchmarks of 20% improvement, and plans a BLA filing for SPS in 1H 2026. Phase 3 portion enrollment of phase 2/3 KYSA-6 registrational study for miv-cel in Myasthenia Gravis is set for end of 2025, with updated phase 2 portion data expected in 2026.
Read More
KYTX Stock Rallies 23% on Upbeat Stiff Person Syndrome Study Data
Published: December 16, 2025 by: Zacks Investment Research
Sentiment: Positive
Kyverna Therapeutics shares jump 23% after a registrational phase II study of miv-cel meets primary and all secondary efficacy goals for treating stiff person syndrome.
Read More
5 High-Risk, High-Reward Biotech Breakthrough Stocks to Watch in 2026
Published: December 16, 2025 by: Zacks Investment Research
Sentiment: Positive
After a weak first half, the drug and biotech sector has recovered in the past 2-3 months with large drugmakers like Pfizer, AstraZeneca, Eli Lilly and Novo Nordisk signing drug pricing agreements with the Trump administration. A rebound in mergers and acquisitions (M&A) has also increased investor confidence in the industry.
Read More
Kyverna Therapeutics: Miv-Cel Delivers Breakthrough Data In Stiff Person Syndrome
Published: December 15, 2025 by: Seeking Alpha
Sentiment: Positive
Kyverna Therapeutics, Inc. shares surged on strong Phase 2 KYSA-8 data for Miv-cel in stiff person syndrome, supporting a bullish outlook. KYTX's Miv-cel achieved significant clinical improvements and eliminated immunotherapy dependence, with a favorable safety profile and no high-grade CRS or ICANS events. A BLA submission for SPS is targeted for 1H26, with FDA approval prospects strengthened by RMAT and Orphan Drug designations.
Read More
Kyverna Therapeutics Announces Positive Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis at AANEM 2025
Published: October 29, 2025 by: GlobeNewsWire
Sentiment: Neutral
Compelling results set new clinical standard in generalized myasthenia gravis (gMG), increasing confidence in the Company's registrational KYSA-6 Phase 3 MG trial
Read More
Kyverna Therapeutics Highlights Potential of KYV-101 in Multiple Sclerosis with Data from Phase 1 Investigator-Initiated Trials to be Presented at ECTRIMS
Published: September 24, 2025 by: GlobeNewsWire
Sentiment: Neutral
KYV-101 IIT data demonstrate promising clinical activity, including robust CAR T penetration into the central nervous system (CNS) and improved expanded disability status scale scores (EDSS)
Read More
Kyverna Therapeutics to Highlight Interim Phase 2 Data from KYV-101 KYSA-6 Study in Myasthenia Gravis at AANEM 2025
Published: September 15, 2025 by: GlobeNewsWire
Sentiment: Neutral
Oral presentation to include topline efficacy and safety data for 6 patients with up to 9 months of follow up
Read More
KYVERNA ALERT: Bragar Eagel & Squire, P.C. is Investigating Kyverna Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Published: July 02, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, July 02, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Kyverna Therapeutics, Inc. (NASDAQ: KYTX) on behalf of long-term stockholders following a class action complaint that was filed against Kyverna on December 9, 2024 with a Class Period pursuant and/or traceable to the Company's offering documents issued in connection with its initial public offering (“IPO”) conducted on February 8, 2024. Our investigation concerns whether the board of directors of Kyverna have breached their fiduciary duties to the company.
Read More
KYVERNA ALERT: Bragar Eagel & Squire, P.C. is Investigating Kyverna Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Published: May 15, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Kyverna Therapeutics, Inc. (NASDAQ: KYTX) on behalf of long-term stockholders following a class action complaint that was filed against Kyverna on December 9, 2024 with a Class Period pursuant and/or traceable to the Company's offering documents issued in connection with its initial public offering (“IPO”) conducted on February 8, 2024. Our investigation concerns whether the board of directors of Kyverna have breached their fiduciary duties to the company.
Read More
Kyverna: 2 Myasthenia Gravis Program Catalysts On Deck In 2025
Published: March 21, 2025 by: Seeking Alpha
Sentiment: Positive
Interim data from phase 2 KYSA-6 study, using KYV-101 for the treatment of patients with Myasthenia Gravis, expected 2nd half of 2025. The global Myasthenia Gravis market is expected to generate sales of $6.7 billion by 2032. Release of topline data from phase 2 KYSA-8 study, using KYV-101 for the treatment of patients with Stiff Person Syndrome, expected in 1st half of 2026.
Read More
About Kyverna Therapeutics, Inc. (KYTX)
- IPO Date 2024-02-09
- Website https://kyvernatx.com
- Industry Biotechnology
- CEO Warner Biddle
- Employees 112